1. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
- Author
-
Toshio, Shimizu, Takako Eguchi, Nakajima, Noboru, Yamamoto, Kan, Yonemori, Takafumi, Koyama, Shunsuke, Kondo, Yu, Sunakawa, Naoki, Izawa, Yoshiki, Horie, Silong, Xiang, Siying, Xu, Lan, Qin, John, Gong, and David, Liu
- Subjects
Pharmacology ,Japan ,Oncology ,Neoplasms ,Programmed Cell Death 1 Receptor ,Antibodies, Monoclonal ,Humans ,Pharmacology (medical) ,Antibodies, Monoclonal, Humanized ,Immune Checkpoint Inhibitors - Abstract
Envafolimab is the first and only globally approved subcutaneously injectable PD-L1 antibody. This open-label, multicenter Phase 1 trial assessed the safety, tolerability, pharmacokinetic (PK) profile, and efficacy of envafolimab as a single agent in Japanese patients with advanced solid tumors. In the dose-escalation phase, 10 patients received subcutaneous (SC) envafolimab QW at 1.0 mg/kg, 2.5 mg/kg and 5.0 mg/kg. In the dose-expansion phase, 16 patients were treated at 2.5 or 5.0 mg/kg Q2W in part-1 and 9 patients received SC envafolimab 300 mg Q4W in part-2. No dose-limiting toxicities (DLTs) were reported. Envafolimab was well tolerated and no new safety signals were identified compared with other marketed products of the same class. Three patients reported Grade ≥ 3 envafolimab-related treatment-emergent adverse events (TEAE), including adrenal insufficiency, cerebral infarction, and immune-mediated enterocolitis. Envafolimab demonstrated dose-proportional increases in area under the time-concentration curve (AUC) and maximum serum concentration (C
- Published
- 2022